27.50

1.84% -0.515

Apollomics Inc (APLM)

Overview News Price History Why APLM Down? Discussions Forecast

Apollomics Inc stock is traded at $27.50, with a volume of 1,516. It is down -1.84% in the last 24 hours and up +56.44% over the past month. Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.

Previous Close:

$28.01

Open:

$27.495

24h Volume:

1,516

Relative Volume:

0.06

Market Cap:

$79.63M

Revenue:

$8.50M

Net Income/Loss:

$-10.94M

P/E Ratio:

-3.6321

EPS:

-7.57

Net Cash Flow:

$-28.76M

1W Performance:

+3.36%

1M Performance:

+56.44%

6M Performance:

+34.06%

1Y Performance:

+401.73%

1-Day Range:

$27.50

1-Week Range:

$26.04

$28.29

52-Week Range:

$5.08

$42.12

Apollomics Inc Stock (APLM) Company Profile

Name

Apollomics Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

Address

Employee

Twitter

Next Earnings Date

2026-07-24

Latest SEC Filings

APLM's Discussions on Twitter

Compare APLM vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
APLM Apollomics Inc	27.50	68.26M	8.50M	-10.94M	-28.76M	-7.57
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Apollomics Inc Stock (APLM) Latest News

Aug 21, 2026

Apollomics Inc. Class A Ordinary Shares (NASDAQ: APLM) Stock Price, News & Analysis - Kalkine

Aug 21, 2026

Aug 19, 2026

Insiders Of Apollomics Are Up 69% On Their US$7.95m Purchase - simplywall.st

Aug 19, 2026

Apollomics, Inc. announced that it has received $8.00001 million in funding from Maxpro Investment Co., Ltd. and other investors. - marketscreener.com

Aug 19, 2026

Biotech Apollomics (APLM) raises $10M in private offering - Stock Titan

Aug 19, 2026

Aug 18, 2026

Apollomics Company Profile & Introduction - Moomoo

Aug 18, 2026

Monday’s insider activity: Major buys at Cardinal, Apollomics By Investing.com - Investing.com Canada

Aug 18, 2026

Monday’s insider activity: Major buys at Cardinal, Apollomics - Investing.com

Aug 18, 2026

Apollomics Insider Bought Shares Worth $7,550,004, According to a Recent SEC Filing - marketscreener.com

Aug 18, 2026

Aug 17, 2026

Apollomics CFO Peter Lin buys $400,005 in shares By Investing.com - Investing.com Nigeria

Aug 17, 2026

Apollomics (APLM) details Yi‑Kuei Chen’s 4.97% stake after $300,000 share purchase - Stock Titan

Aug 14, 2026

Apollomics (APLM) CFO adds 26,667 shares in private deal - Stock Titan

Aug 14, 2026

Aug 13, 2026

Apollomics (APLM) Edges Higher to $17.37 as Biotech Momentum BuildsPrice Momentum Stocks - vinanet.vn

Aug 13, 2026

Aug 12, 2026

Apollomics (Nasdaq: APLM) lines up $10M private share placement - Stock Titan

Aug 12, 2026

Apollomics raises $10 million in private placement By Investing.com - Investing.com India

Aug 12, 2026

Aug 11, 2026

Apollomics raises $10 million in private placement - Investing.com

Aug 11, 2026

Apollomics Announces $10 Million Private Placement Transaction - GlobeNewswire

Aug 11, 2026